Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SRR10900016

—

09ebfd2a-2129-5fb6-9e45-1e40b13d5ceb

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.400
  • DNA_REPAIR+0.300
  • MYC_TARGETS_V1+0.300
  • OXIDATIVE_PHOSPHORYLATION+0.300
  • UNFOLDED_PROTEIN_RESPONSE+0.300
  • E2F_TARGETS+0.200
  • GLYCOLYSIS+0.200
  • MTORC1_SIGNALING+0.200
  • PANCREAS_BETA_CELLS+0.200
  • PROTEIN_SECRETION+0.200

Top 10 suppressed

  • ALLOGRAFT_REJECTION-0.500
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
  • INTERFERON_GAMMA_RESPONSE-0.500
  • COMPLEMENT-0.400
  • IL6_JAK_STAT3_SIGNALING-0.400
  • INFLAMMATORY_RESPONSE-0.400
  • KRAS_SIGNALING_UP-0.400
  • UV_RESPONSE_DN-0.400
  • ANGIOGENESIS-0.300
  • COAGULATION-0.300

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1BSR_04_0040_A3_S71
breast-umap@18
—B0.882
2SRR10900570
melanoma-umap@29
——0.880
3SRR10900021
melanoma-umap@29
——0.879
4SRR2016943
head-neck@1
——0.878
5TCGA-85-8070-01A-11R-2247-07
lung-landscapes@6
—cohortSQ20.876
6AUR-AFR3-TTM1-A-1-1-R-A743-41
breast-umap@18
—C0.874
720110070.TNBC
breast-umap@18
—E0.874
8TCGA-CQ-6225-01A-11R-1915-07
head-neck@1
——0.873
9MDT-AP-0756
medullo-epn-umap@date-based
MedMedulloblastoma0.868
1064935b9c-623d-40d4-bd89-f2af006b1f92
colon-landscapes@1
——0.867

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 19 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.400Idelalisib— uncovered
DNA_REPAIR0.300Idelalisib— uncovered
MYC_TARGETS_V10.300Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.300Remibrutinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.300Idelalisib— uncovered
E2F_TARGETS0.200Inavolisib— uncovered
GLYCOLYSIS0.200Inavolisib— uncovered
MTORC1_SIGNALING0.200Inavolisib— uncovered
PANCREAS_BETA_CELLS0.200Cobimetinib— uncovered
PROTEIN_SECRETION0.200Remibrutinib— uncovered
UV_RESPONSE_UP0.200Idelalisib— uncovered
ADIPOGENESIS0.100Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.100Remibrutinib— uncovered
FATTY_ACID_METABOLISM0.100Inavolisib— uncovered
HEDGEHOG_SIGNALING0.100Inavolisib— uncovered
HEME_METABOLISM0.100Temsirolimus— uncovered
PEROXISOME0.100Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.100Inavolisib— uncovered
SPERMATOGENESIS0.100Inavolisib— uncovered